iCAD Announces Launch Of iReveal® Breast Density Analysis Solution As Latest Addition To PowerLook Advanced Mammography Platform
NASHUA, N.H., July 7, 2015 /PRNewswire/ -- iCAD, Inc. (Nasdaq: ICAD), an industry-leading provider of advanced image analysis, workflow solutions and radiation therapy for the early identification and treatment of cancer, today announced the launch of the iReveal® breast density module as the latest addition to the Company's PowerLook Advanced Mammography Platform (AMP)®. The iReveal software is designed to deliver automated, rapid and reproducible assessments of breast density to help identify patients that may experience reduced sensitivity to digital mammography due to dense breast tissue.
An estimated 40% of women in the US have dense breast tissue that may mask the presence of cancerous tissue in standard mammography. In women with dense breasts, mammography sensitivity is reduced to approximately 48% from an average of 98%. As breast density increases, the risk of developing breast cancer can also increase according to the American Cancer Society. Currently, legislation has been passed in 22 states requiring physicians to report breast density to patients.
iReveal uses an advanced software program to assess breast density based on the range of categories established by the American College of Radiology's Breast Imaging Reporting and Data System (BI-RADS®), automating the same analytical approach used by many experienced radiologists. In many cases, patients with dense breast tissue may be recommended for additional screening exams including use of breast tomosynthesis.
"The launch of iReveal is another example of iCAD's commitment to meeting the ever-expanding needs of healthcare providers and patients in cancer detection and treatment. This solution offers a standardized breast density measurement that eliminates reader variability and classifies density using the same factors considered by experienced radiologists," said Ken Ferry, CEO of iCAD. "With iReveal, radiologists may be better able to identify women with dense breasts who experience decreased sensitivity to cancer detection with mammography."
Mr. Ferry added, "With the increasing support for the reporting of breast density across the US, there is a significant opportunity to drive adoption of iReveal by existing users of the PowerLook AMP platform and with new customers, which represents an incremental $100 million market opportunity over the next few years. Longer-term, we plan to integrate the iReveal technology into our Tomosynthesis CAD product, which is the next large growth opportunity for our Cancer Detection business."
iCAD's PowerLook AMP platform is a scalable solution providing facilities with the ability to add a range of options in computer aided detection (CAD), lesion analysis tools, automated breast density assessments, quality assurance and resource planning functionality.
About iCAD, Inc.
iCAD delivers innovative cancer detection and radiation therapy solutions and services that enable clinicians to find and treat cancers earlier and faster while enhancing patient care. iCAD offers a comprehensive range of upgradeable computer aided detection (CAD) and workflow solutions to support rapid and accurate detection of breast, prostate and colorectal cancers. iCAD's Xoft® Axxent® Electronic Brachytherapy (eBx®) System® is a painless, non-invasive technology that delivers high dose rate, low energy radiation, which targets cancer while minimizing exposure to surrounding healthy tissue. The Xoft System is FDA cleared and CE marked for use anywhere in the body, including treatment of non-melanoma skin cancer, early-stage breast cancer and gynecological cancers. The comprehensive iCAD technology platforms include advanced hardware and software as well as management services designed to support cancer detection and radiation therapy treatments. For more information, visit www.icadmed.com or www.xoftinc.com.